Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ExPEC9V + HD quadrivalent influenza vaccine
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ExPEC9V + HD quadrivalent influenza vaccine is an investigational combination vaccine being developed by Janssen Vaccines & Prevention (a subsidiary of Johnson & Johnson). The combination consists of **ExPEC9V** (also known as VAC52416 or JNJ-78901563), a 9-valent bioconjugate vaccine targeting extraintestinal pathogenic *Escherichia coli* (ExPEC), and a high-dose (HD) quadrivalent seasonal influenza vaccine. ExPEC9V is designed to prevent invasive ExPEC disease (IED), including bloodstream infections and urosepsis, by targeting nine specific E. coli O-serotypes (O1, O2, O4, O6, O15, O16, O18, O25, and O75). The high-dose quadrivalent influenza component provides protection against four seasonal influenza virus strains. The combination is currently in Phase 3 clinical development, specifically being evaluated in adults aged 65 years and older to assess the safety and immunogenicity of co-administration compared to separate administration of the two vaccines.
- Other names
- ExPEC9V + high-dose quadrivalent influenza vaccineVAC52416 + HD quadrivalent influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on ExPEC9V + HD quadrivalent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExPEC9V + HD quadrivalent influenza vaccine.